Literature DB >> 3604393

Evaluation of vaccination requirements to secure continuous antitoxin immunity to tetanus.

O Simonsen, M W Bentzon, K Kjeldsen, H A Venborg, I Heron.   

Abstract

To investigate minimal requirements for tetanus revaccination to secure continuous protection, recently recommended by WHO, 637 subjects with documented vaccination history were studied. Antitoxin concentration in serum relative to time corresponded to a steep decline in the first years after vaccination continuing exponentially. By multiple regression analyses duration of immunity after three-dose primary vaccination was calculated to be 5 years (upper 95% confidence limit of estimated risk of serum antitoxin concentration below 0.01 IU ml-1 still less than 0.1%). Serum antitoxin concentration relative to time after revaccination depended upon age at revaccination and interval from primary vaccination. When given in childhood 5 years after primary vaccination revaccination was calculated to offer protection for approximately equal to 21 years, but protection was considerably shorter when given to the elderly. Cross-sectional and longitudinal analyses were compared and statistical approaches were introduced which may be generally applicable for evaluation of vaccination programmes. It was concluded that a vaccination programme consisting of primary vaccination in infancy and one revaccination 5 years later will secure continuous protection to about the age of 25 years. This is considerably simpler than programmes recommended in many countries, in which risk of hyperimmunization is apparent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3604393     DOI: 10.1016/0264-410x(87)90057-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Anyone for tetanus?

Authors:  J G Howie
Journal:  BMJ       Date:  1988-09-03

2.  Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.

Authors:  M Anthony Moody; Sampa Santra; Nathan A Vandergrift; Laura L Sutherland; Thaddeus C Gurley; Mark S Drinker; Ashley A Allen; Shi-Mao Xia; R Ryan Meyerhoff; Robert Parks; Krissey E Lloyd; David Easterhoff; S Munir Alam; Hua-Xin Liao; Brandy M Ward; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Robert A Seder; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

3.  Detection of tetanus antitoxin using Eu(3+)-labeled anti-human immunoglobulin G monoclonal antibodies in a time-resolved fluorescence immunoassay.

Authors:  J P Schröder; W D Kuhlmann
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

4.  Predictors of the immune response to booster immunisation against tetanus in Czech healthy adults.

Authors:  M Petráš; V Oleár
Journal:  Epidemiol Infect       Date:  2018-08-23       Impact factor: 4.434

5.  Some unanswered questions about vaccination.

Authors:  F Brown
Journal:  FEMS Microbiol Lett       Date:  1992-12-15       Impact factor: 2.742

6.  Tetanus disease and deaths in men reveal need for vaccination.

Authors:  Shona Dalal; Julia Samuelson; Jason Reed; Ahmadu Yakubu; Buhle Ncube; Rachel Baggaley
Journal:  Bull World Health Organ       Date:  2016-06-02       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.